Mildronate (Meldonium, THP, MET-88, Mildronats, Quaterine) is an anti-ischemic metabolic agent. Due to its unique mechanism of action Mildronate is widely used for treatment of different heart and vascular diseases, for the improvement of work capacity of generally healthy people at physical and mental overloads and during rehabilitation period. Its active pharmaceutical ingredient (active substance) is meldonium which is responsible for the pharmacological and therapeutic effects of Mildronate. Proffesor Dr. chem. hab. Ivars Kalvins is the scientist behind Mildronate, who invented this anti-ischemic drug back in 1970’s. Ivars Kalvins is a former director of the Latvian Institute of Organic Synthesis and is recognized as one of the leading Latvian and European scientists. Currently he is acting as a Chairman of Scientific Council of Latvian Institute of Organic Synthesis.
- Improves Oxygen Delivery to Cells.
- Excellent for Sportsmen to Improve Stamina.
- Protects Cells from Intoxication.
- Improves Energy Levels and Faster Physical Recovery.
- Treat Chronic Heart Failure and Cerebral Strokes.
- Abstinence Syndrome.
Mr Kalvins’s interests of inventing include new physiologically active substances for CNS, cardiovascular and oncologic diseases, heterocyclic compounds and amino acid analogues in chemistry, biochemical mechanisms of action for new medicinal substances, immunochemistry.
Meldonium is a cytoprotective substance, which is used to prevent death of ischemic cells. Its mechanism of action is based on the regulation of energy metabolism pathways thorough L-carnitine lowering effect. L-carnitine biosynthesis enzymes gamma-butyrobetaine hydroxylase and carnitine/organic cation transporter type 2 (OCTN2) are the main known drug targets of meldonium, and through inhibition of these 2 targets meldonium optimizes cellular energy homeostasis. Free fatty acid inhibition is not a direct pharmacological target of meldonium. However, since L-carnitine is involved in metabolism of fatty acids, the decline in its levels stimulates glucose metabolism and decreases concentrations of potentially harmful L-carnitine related metabolites, such as long-chain acylcarnitines and trimethyl-N-oxide.
This is important in the treatment of pathologies associated with ischemia (stenocardia, heart failure, stroke), as in these cases the tissues and cells are not getting enough oxygen and nutrients.
PACKAGING & DOSAGE
Mildronate comes in capsules.
As part of combined therapy: 500-1000 mg once a day (or divide the daily dose for 2 times a day). Period of therapy is 4-6 weeks.
Chronic disorders of cerebral circulation: 500 mg once a day. Period of therapy is 4-6 weeks.
Intellectual and physical stress: 250 mg four times a day. Period of therapy is 10-14 days.
Sportsmen: 500-1000 mg two times a day before training. Duration of treatment during preparatory period is 2-3 weeks, during the period of competition 10-14 days.
Chronic alcoholism: 500 mg four times a day. Period of therapy is 7-10 days.
Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.